Literature DB >> 30105153

Reader response: Pimavanserin: A novel therapeutic option for Parkinson disease psychosis.

Abigail C Keys Lawler1, Yasar Torres-Yaghi1, Fahd Amjad1, Charbel Moussa1, Fernando Pagan1.   

Abstract

Entities:  

Year:  2018        PMID： 30105153      PMCID： PMC6075992          DOI： 10.1212/CPJ.0000000000000467

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN： 2163-0402


× No keyword cloud information.
  3 in total

1.  Serotonin 2A receptors and visual hallucinations in Parkinson disease.

Authors:  Benedicte Ballanger; Antonio P Strafella; Thilo van Eimeren; Mateusz Zurowski; Pablo M Rusjan; Sylvain Houle; Susan H Fox
Journal:  Arch Neurol       Date:  2010-04

2.  Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.

Authors:  Jeffrey Cummings; Stuart Isaacson; Roger Mills; Hilde Williams; Kathy Chi-Burris; Anne Corbett; Rohit Dhall; Clive Ballard
Journal:  Lancet       Date:  2013-11-01       Impact factor: 79.321

Review 3.  Pimavanserin: A novel therapeutic option for Parkinson disease psychosis.

Authors:  Trevor Hawkins; Brian D Berman
Journal:  Neurol Clin Pract       Date:  2017-04
  3 in total
  1 in total

1.  Genetic and epigenetic analysis of the serotonin 2A receptor in the context of cocaine abuse.

Authors:  Aysheh Alrfooh; Ryan M Smith
Journal:  Epigenetics       Date:  2021-11-23       Impact factor: 4.861
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.